Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Hengrui Medicine

Status and phase: Completed; Phase 3

Conditions: Severe Aplastic Anemia

Treatments: Drug: Placebo+Standard Therapy; Drug: Hetrombopag Olamine+Standard Therapy

Study type: Interventional

Funder types: Industry

Identifiers

NCT03825744

HR-TPO-SAA-III

Details and patient eligibility

About

This is a multicenter, randomized, placebo-control, phase III study to investigate hetrombopag in subjects with severe AA who are treated naive.

180 treated naive patients with SAA will be enrolled in the study. The primary objective of the study will be the rate of complete hematologic response at six months.

Enrollment: 240 patients

Sex: All

Ages: 15 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1.15 Years to 75 Years (weight greater than 50 kg if Age < 18 years old). 2.Severe aplastic anemia characterized by Bone marrow cell proliferation less than 25 percent (If ≥25% but <50%, the remaining hematopoietic cells should be <30%) AND At least two of the following: Absolute neutrophil count <0.5×109/L; Platelet count <20×109/L; Absolute reticulocyte count <20×109/L.

3.Unsuitable or unwilling to perform hematopoietic stem cell transplantation (HSCT).

4.Signed informed consent.

Exclusion criteria

1. Diagnosis of whole blood cell reduction due to other causes or bone marrow hypoproliferative diseases.
2. Subjects who have previously received immunosuppressive therapy with mycophenolate mofetil, sirolimus, high dose cyclophosphamide (≥45mg/kg/d), alemtuzumab, etc；or have treated with thrombopoietin receptor agonist (eg, eltrombopag, romiplostim, rhTPO, etc.) prior to randomization.
3. Previous history of hematopoietic stem cell transplantation.
4. Subjects who is known or suspected of contraindications or hypersensitivity to Hetrombopag's API (Active Pharmaceutical Ingredient).
5. Evidence of clonal cytogenetic abnormalities at the time of screening.
6. Bleeding and/or Infection not adequately responding to appropriate therapy.
7. Any laboratory or clinical evidence for HIV infection. Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subjects screening.
8. ALT> 2.5 x upper limit of normal (ULN), AST> 2.5 x upper limit of normal (ULN) DBLI> 1.5 x upper limit of normal (ULN), Scr> upper limit of normal (ULN).
9. Subjects with uncontrolled hypertension (>180/100mmHg), severe arrhythmia (such as complete left bundle branch block, QT interval prolongation (Bazetts formula), torsade ventricular tachycardia, etc.), unstable angina, pulmonary hypertension at the time of screening.
10. Subjects diagnosed with cirrhosis or portal hypertension.
11. Subjects with malignant solid tumors of any organ system within 5 years prior to screening, with or without treatment, metastasis or recurrence, except for local cutaneous basal cell carcinoma; subjects with hematological tumors found previously or during screening.
12. Subjects with deep vein thrombosis, myocardial infarction, stroke or peripheral arterial embolization within 12 months prior to randomization.
13. Female subjects who are nursing or pregnant.
14. Subjects cannot comply with effective contraception.
15. Subjects have participated in other clinical trial within the 3 months prior to study entry.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

240 participants in 2 patient groups, including a placebo group

Hetrombopag Olamine+Standard Therapy

Experimental group

Treatment:

Drug: Hetrombopag Olamine+Standard Therapy

Placebo+Standard Therapy

Placebo Comparator group

Treatment:

Drug: Placebo+Standard Therapy